When there’s no registry: Building rare disease evidence that supports regulatory scrutiny
A look at building rare disease evidence across countries and data sources when no established registry or natural history dataset exists.
<span class="vcard">tatiana.sachs@bcplatforms.com</span>
-
Read more
-
BC Platforms recognized among TIME’s World’s Top HealthTech Companies 2026
Read moreBC Platforms has been recognized among TIME’s World’s Top HealthTech Companies 2026 in AI & Data Analytics for the second consecutive year.
-
BC Platforms named one of the Top AWS Partners to Watch in 2026
Read moreBC Platforms has been recognized as one of the Top AWS Partners to Watch in 2026 by CIO Times.
-
BC Platforms launches BC Mosaic App Store to empower data scientists and healthcare researchers with innovative analytics and workflow applications
Read moreBC Platforms launches the BC Mosaic App Store, a certified ecosystem of analytics, AI, and research applications within its TRE.
-
What comes next for clinical trials? Mukhtar Ahmed says “personalized research”
Read moreMukhtar Ahmed discusses how AI, real-world data, and federated analytics could accelerate the shift to personalized research.
-
BC Platforms named Advanced Drug Development Technology Of The Year in Europe 2026
Read moreBC Platforms has been recognized by Pharma Tech Outlook Europe for leadership in evidence generation and AI-enabled drug development.